期刊文献+

慢加急性重型乙型病毒性肝炎患者血清干扰素γ水平的检测及临床意义 被引量:6

Diagnostic Value and Clinical Significance of Serum Interferon-gamma in Patients with Acute-On-Chronic Hepatitid B Liver Failure
原文传递
导出
摘要 目的:探讨血清干扰素-γ(IFN-γ)在慢加急性重型乙型病毒性肝炎(acute-on-chroni hepatitis B lover failure,ACHBLF)发病中的作用,旨在为ACHBLF的诊治提供理论参考。方法:采用ELSIA法测定30例ACHBLF患者和30例CHB患者血清IFN-γ水平,采用全自动生化仪检测肝功能常规指标。结果:ACHBLF组IFN-γ水平显著高于CHB组,相比较有显著性差异(P<0.05);ACHBLF组TBIL、ALT水平显著高于CHB组,相比较有显著性差异(P<0.05);ACHBLF组PTA水平显著低于CHB组,相比较有显著性差异(P<0.05);ACHBLF患者的IFN-γ水平与TBIL呈显著正相关(r=0.818,P<0.01),与PTA呈显著负相关(r=-0.529,P<0.05),而与ALT无明显相关性(r=0.172,P>0.05)。结论:IFN-γ参与ACHBLF的发病,并且是ACHBLF病情严重程度的重要指标之一。 Objective: To explore the diagnostic value and clinical significance of serum interferon-gamma (IFN-γ) in patients with acute-on-chronic hepatitid B liver failure (ACHBLF), and provide theoretical reference for the diagnosis and treatment of ACHBLF. Methods:The serum IFN-γ level of 30 cases of ACHBLF and 30 cases of CHB were detected by e ce lmmunoassay (ECLIA), the conventional indicators of liver function were detected by automatic biochemical analyzer. Results:The IFN-γlevel of ACHBLF group was higher than the CHB group, and the difference was significant (P〈0.05); The TBIL and ALT levels of ACHBLF group were higher than the CHB group, and the difference was significant (P 〈0.05); The PTA level of ACHBLF group was lower than the CHB group, and the difference was significant (P〈0.05). The IFN-γlevel had significant positive correlation with TBIL (r = 0.818, P〈0.01), and negative correlation with PTA (r = -0.529, P〈0.05) but no correlation with ALT (r = 0.172, P〉0.05). Conclusions: The IFN-γ involves in the pathogenesis of ACHBLF, and is an important indicator for evaluating the severity of ACHBLF.
出处 《现代生物医学进展》 CAS 2012年第28期5460-5462,共3页 Progress in Modern Biomedicine
基金 国家"十二五"科技重大专项课题基金(2012ZX10002-003)
关键词 慢加急性重型乙型病毒性肝炎 干扰素Γ 肝炎 Acute-on-chronic hepatifid B liver failure Interferon-gamma Hepatitid
  • 相关文献

参考文献7

二级参考文献67

共引文献15404

同被引文献73

  • 1李奕鑫,潘兴南,杨红,陈育霞,刘理冠.干扰素联合胸腺素α1治疗HBeAg阳性慢性乙型肝炎52周疗效分析[J].中华临床感染病杂志,2011,4(1). 被引量:1
  • 2Tsuda M, Mofitoki Y, Lian ZX, et al. Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid [J]. Hepatology,2012,55 (2):512-521.
  • 3Kim BH, Kim YJ, Jeong SH, et al. Clinical features of autoimmune hepatitis and comparison of two diagnostic criteria in Korea: a nationwide, multicenter study[J]. J Gastroenterol Hepatol,2013,28 (1): 128-134.
  • 4Guo X, Xiong L, Zou L, et al. Up regulation of bone morphogenetic protein 4 is associated with poor prognosis in patients with hepatocellular carcinoma[J]. Pathol Oncol Res,2012,18(3):635-640.
  • 5Honda A, Ikegami T, Nakamuta M, et al. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid[J]. Hepatology,2013,57(5): 1931-1941.
  • 6Ere C, Ozaslan E, Wahlin S, et al. Antibodies to soluble liver antigen in patients with various liver diseases: a multicentre study [J]. Liver Int,2013,33(2): 190-196.
  • 7Dilger K, Hohenester S, Winkler-Budenhofer U, et al. Effect of ursodeoxyeholic acid on bile acid profiles and intestinal detoxificafion machinery in primary biliary cirrhosis and health [J]. J Hepatol,2012,57(1): 133-140.
  • 8Myers RP, Swain MG, Lee SS, et al. B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid[J]. Am J Gastroenterol,2013,108(6):933-841.
  • 9Welz PS, Wullaert A, Vlantis K, et al. FADD prevents RIP3-mediated epithelial cell necrosis and chronic intestinal inflammation[J]. Nature, 2011,477(7364):330-334.
  • 10Invernizzi P, Ransom M, Rayehaudhuri S, et al. Classical HLA-DRB 1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis[J]. Genes Immun,2012,13(6):461-468.

引证文献6

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部